Clinical Trial Update: Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating JTX-4014 alone and in combination with vopratelimab in biomarker-selected metastatic non-small cell lung cancer after one prior plati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JTX-4014
• Vopratelimab (vopratelimab)

Snippet

Sponsor: Jounce Therapeutics, Inc. | Conditions: NSCLC | Phase 2 | Status: TERMINATED